{"id":4809,"date":"2021-05-25T19:44:33","date_gmt":"2021-05-25T23:44:33","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/"},"modified":"2024-12-03T14:57:43","modified_gmt":"2024-12-03T19:57:43","slug":"considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/","title":{"rendered":"Considering Frailty in Sars-CoV-2 Vaccine Development: How Geriatricians Can Assist"},"content":{"rendered":"<h2 class=\"title\">Abstract<\/h2>\n<div id=\"enc-abstract\" class=\"abstract-content selected\">\n<p>The COVID-19 pandemic has disproportionately impacted frail older adults, especially residents of long-term care (LTC) facilities. This has appropriately led to prioritization of frail older adults and LTC residents, and those who care for them, in the vaccination effort against COVID-19. Older adults have distinct immunological, clinical, and practical complexity, which can be understood through a lens of frailty. Even so, frailty has not been considered in studies of COVID-19 vaccines to date, leading to concerns that the vaccines have not been optimally tailored for and evaluated in this population even as vaccination programs are being implemented. This is an example of how vaccines are often not tested in Phase 1\/2\/3 clinical trials in the people most in need of protection. We argue that geriatricians, as frailty specialists, have much to contribute to the development, testing and implementation of COVID-19 vaccines in older adults. We discuss roles for geriatricians in ten stages of the vaccine development process, covering vaccine design, trial design, trial recruitment, establishment and interpretation of illness definitions, safety monitoring, consideration of relevant health measures such as frailty and function, analysis methods to account for frailty and differential vulnerability, contributions in regulatory and advisory roles, post-marketing surveillance, and program implementation and public health messaging. In presenting key recommendations pertinent to each stage, we hope to contribute to a dialogue on how to push the field of vaccinology to embrace the complexity of frailty. Making vaccines that can benefit frail older adults will benefit everyone in the fight against COVID-19.<\/p>\n<\/div>\n","protected":false},"author":19,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[],"class_list":["post-4809","ccna_publication","type-ccna_publication","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Considering Frailty in Sars-CoV-2 Vaccine Development: How Geriatricians Can Assist - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Considering Frailty in Sars-CoV-2 Vaccine Development: How Geriatricians Can Assist - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"Abstract The COVID-19 pandemic has disproportionately impacted frail older adults, ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-03T19:57:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/\",\"name\":\"Considering Frailty in Sars-CoV-2 Vaccine Development: How Geriatricians Can Assist - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\"},\"datePublished\":\"2021-05-25T23:44:33+00:00\",\"dateModified\":\"2024-12-03T19:57:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ccna-ccnv.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Considering Frailty in Sars-CoV-2 Vaccine Development: How Geriatricians Can Assist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Considering Frailty in Sars-CoV-2 Vaccine Development: How Geriatricians Can Assist - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/","og_locale":"fr_CA","og_type":"article","og_title":"Considering Frailty in Sars-CoV-2 Vaccine Development: How Geriatricians Can Assist - CCNA - CCNV","og_description":"Abstract The COVID-19 pandemic has disproportionately impacted frail older adults, ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/","og_site_name":"CCNA - CCNV","article_modified_time":"2024-12-03T19:57:43+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/","name":"Considering Frailty in Sars-CoV-2 Vaccine Development: How Geriatricians Can Assist - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2021-05-25T23:44:33+00:00","dateModified":"2024-12-03T19:57:43+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/considering-frailty-in-sars-cov-2-vaccine-development-how-geriatricians-can-assist-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Considering Frailty in Sars-CoV-2 Vaccine Development: How Geriatricians Can Assist"}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/4809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/19"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=4809"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=4809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}